Deferasirox (Exjade)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Deferasirox

What it is

Deferasirox is an oral iron chelator: it binds excess iron so the body can pass it out in the stool. It is used for iron overload caused by regular blood transfusions, for example in thalassaemia or sickle cell disease, and for iron overload in some non-transfusion conditions. It is sold as Exjade and Jadenu.

How genes come into it

Deferasirox is cleared mainly by the enzymes UGT1A1 and UGT1A3 and pumped into bile by ABCC2 and ABCG2. A small group of studies, many from one research group in thalassaemia, have looked at these genes and at CYP24A1, CYP1A2 and the vitamin D receptor VDR for blood levels, response and kidney or liver side effects. There is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Deferasirox. Upload your DNA file to see which of these rows apply to you.

Rated evidence (19 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

UGT1A3 rs3806596: Level 3. Efficacy, Metabolism/PK: Beta-thalassemia and related diseases. 3.

ABCG2 rs13120400: Level 3. Efficacy, Metabolism/PK: Beta-thalassemia and related diseases. 3.

CYP24A1 rs2248359: Level 3. Metabolism/PK: Beta-thalassemia and related diseases. 2.

UGT1A1 rs887829: Level 3. Metabolism/PK: Beta-thalassemia and related diseases. 2.

Metabolism (26 findings)

Studies of how quickly the body processes this medication.

ABCC2 rs2273697: Genotype AG is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype GG.

ABCC2 rs2273697: Genotype AG is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG.

ABCG2 rs13120400: Genotypes CT + TT is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype CC.

ABCG2 rs13120400: Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.

Response (7 findings)

Studies of how well it worked in people carrying a variant.

CYP27B1 rs10877012: Genotype GG is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes GT + TT.

GC rs7041: Genotype AA is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes AC + CC.

UGT1A1 rs887829: Genotype CC is associated with decreased response to deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.

UGT1A3 rs1983023: Genotype TT is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Ferriprox (Iron Chelators)

Accupril (ACE Inhibitors)

ACE Inhibitors (class) (ACE Inhibitors)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com